Organon Says Interim MIUDELLA Study Results Cover Six Years of Use
Organon said Sebela Women’s Health will present interim results from an ongoing Phase 3 study of its hormone-free copper IUD, MIUDELLA, through six years of use.
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Women’s Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA®, a hormone-free, copper intrauterine devi…